Search

Daratumumab, a CD38 monoclonal antibody study in advanced multiple myeloma – an open-label, dose escalation followed by open-label extension in a single-arm phase I/II study

Daratumumab is a human CD38 monoclonal antibody being tested against multiple myeloma, but it could also have potential in a broad range of other hematological diseases.

Read more

Promising results in trials with non-chemotherapy treatments for Leukemias to be presented at the 18th Congress of the European Hematology Association in Stockholm, June 13-16, 2013

What is new? Current investigations are aimed at evaluating the use of monoclonal antibodies (mAB). These mABs bind to specific molecules (antigens) found on leukemic cells. This results in immune destruction of the leukemic cells.

Read more

Abstract & Clinical Case Submission and Travel Grant

Submit your abstract here

Abstract and clinical case procedurePlease note that the submission of an abstract constitutes a formal commitment by the presenting author to present the abstract (if accepted) orally or as a poster in the session at the time…

Read more

EHA2024 Hybrid Congress

Thank you all for joining us in Madrid for the 29th European Hematology Association Congress!

The EHA2024 Congress platform is now closed. You may browse selected content through the EHA Library, EHA Open access library.

Read more

EHA’s advocacy for hematology continues

The EHA Board has recently approved five position papers which formulate EHA’s key lobbying priorities:

Support for hematology research in Horizon 2020 (and future EU research funding programs)
Access to treatment for patients with blood disorders
EU collaboration to reduce the prices…

Read more